Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (Q33956990)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

plasma cell leukemia

1 reference

based on heuristic

inferred from title

object named as

J Caers

19

0 references

object named as

R Fonseca

31

0 references

Giampaolo Merlini

object named as

G Merlini

32

0 references

object named as

R Hajek

7

0 references

Athanasios Dimopoulos

22

object named as

M A Dimopoulos

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

International Myeloma Working Group

37

object named as

International Myeloma Working Group

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

object named as

R A Kyle

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

object named as

S Usmani

5

0 references

Robert Z Orlowski

35

object named as

R Z Orlowski

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

3

object named as

B G M Durie

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

C Fernández de Larrea

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

H Ludwig

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D H Vesole

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J F San Miguel

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

O Sezer

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

P Sonneveld

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S K Kumar

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Mahindra

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

R Comenzo

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Palumbo

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Mazumber

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

K C Anderson

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

P G Richardson

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Z Badros

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Cavo

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

X LeLeu

21

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C S Chim

23

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

R Schots

24

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Noeul

25

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D Fantl

26

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

U-H Mellqvist

27

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

O Landgren

28

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Chanan-Khan

29

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

P Moreau

30

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J J Lahuerta

33

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Bladé

34

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J J Shah

36

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

21 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

780-791

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

How I treat plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Primary plasma cell leukemia and autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Thirty patients with primary plasma cell leukemia: a single center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Genetic aberrations and survival in plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Primary plasma cell leukaemia: a report of 18 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

First case of plasma-cell leukemia co-existing with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Up-regulation of IL-6-receptors by IL-3 on a plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Primary plasma cell leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Plasma cell leukaemia. Diagnostic problems in our experience with 11 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Plasma cell leukemia. Report on 17 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Plasma cell leukemia: an evaluation of response to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Interleukin-6 dependence of advanced malignant plasma cell dyscrasias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

Multiple myeloma: review of 869 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

28 July 2018

A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Extravasation and homing mechanisms in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Plasma-cell leukemia and human herpesvirus 8 infection.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Frequent upregulation of MYC in plasma cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Differential repetitive DNA methylation in multiple myeloma molecular subgroups.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Bortezomib is an efficient agent in plasma cell leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112539

29 October 2018

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.336

21 January 2018

Plasma cell leukemia (PCL): A report on 15 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of the c-myc oncogene in human plasma-cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Highly complex chromosomal abnormalities in plasma cell leukemia as detected by FISH technique

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of bortezomib in patients with plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyclonal reactive peripheral blood plasmacytosis mimicking plasma cell leukemia in a patient with Staphylococcal sepsis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of aggressive plasma cell leukaemia under interferon-alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythrophagocytosis in a case of plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Primary plasma cell leukemia (IgD-lambda) with hyperammonemia]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2012.336

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33956990&oldid=2196051757"